Valley Brook Capital Group Inc. Takes Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• Valley Brook Capital Group Inc. acquired a new stake in IDEXX Laboratories, purchasing 425 shares valued at approximately $228,000 during the 2nd quarter.
• Insider transactions recently included a significant sale by EVP Nimrata Hunt of 7,143 shares worth over $4.5 million, reflecting a 28.40% decrease in their holdings.
• IDEXX Laboratories posted a strong earnings report for the previous quarter, with earnings per share of $3.63, outpacing analyst estimates and indicating a 10.6% year-over-year revenue growth.

Valley Brook Capital Group Inc. acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 425 shares of the company's stock, valued at approximately $228,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Red Spruce Capital LLC lifted its stake in shares of IDEXX Laboratories by 1.1% in the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company's stock valued at $912,000 after purchasing an additional 19 shares in the last quarter. Rise Advisors LLC lifted its stake in shares of IDEXX Laboratories by 3.9% in the 2nd quarter. Rise Advisors LLC now owns 562 shares of the company's stock valued at $301,000 after purchasing an additional 21 shares in the last quarter. Blue Trust Inc. lifted its stake in shares of IDEXX Laboratories by 14.2% in the 2nd quarter. Blue Trust Inc. now owns 177 shares of the company's stock valued at $95,000 after purchasing an additional 22 shares in the last quarter. Sage Mountain Advisors LLC lifted its stake in shares of IDEXX Laboratories by 3.8% in the 1st quarter. Sage Mountain Advisors LLC now owns 635 shares of the company's stock valued at $267,000 after purchasing an additional 23 shares in the last quarter. Finally, Great Lakes Advisors LLC lifted its stake in shares of IDEXX Laboratories by 0.9% in the 1st quarter. Great Lakes Advisors LLC now owns 2,567 shares of the company's stock valued at $1,078,000 after purchasing an additional 23 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Nimrata Hunt sold 7,143 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total value of $4,503,161.49. Following the completion of the sale, the executive vice president directly owned 18,007 shares in the company, valued at approximately $11,352,153.01. The trade was a 28.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director M Anne Szostak sold 2,187 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the completion of the sale, the director owned 262 shares of the company's stock, valued at $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock worth $34,293,468 over the last 90 days. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $616.15 on Friday. The business's 50 day moving average is $641.49 and its two-hundred day moving average is $542.72. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $688.12. The firm has a market cap of $49.30 billion, a price-to-earnings ratio of 51.30, a PEG ratio of 3.99 and a beta of 1.58. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the company posted $2.44 EPS. IDEXX Laboratories's quarterly revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on IDXX. JPMorgan Chase & Co. lifted their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a research note on Monday, August 4th. Stifel Nicolaus set a $640.00 price target on IDEXX Laboratories in a research report on Monday, August 4th. Weiss Ratings reissued a "buy (b-)" rating on shares of IDEXX Laboratories in a research report on Wednesday. Jefferies Financial Group began coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price target on the stock. Finally, Piper Sandler reissued a "neutral" rating and set a $700.00 price target (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $656.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.